Hennion & Walsh Asset Management Inc. Has $4.33 Million Position in Ocugen, Inc. $OCGN

Hennion & Walsh Asset Management Inc. lifted its holdings in shares of Ocugen, Inc. (NASDAQ:OCGN) by 121.7% during the 2nd quarter, Holdings Channel.com reports. The firm owned 2,830,397 shares of the company’s stock after purchasing an additional 1,553,672 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Ocugen were worth $4,331,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Ocugen by 3.1% in the third quarter. Vanguard Group Inc. now owns 15,223,585 shares of the company’s stock valued at $24,814,000 after buying an additional 450,904 shares during the last quarter. Millennium Management LLC grew its holdings in Ocugen by 29.7% during the 4th quarter. Millennium Management LLC now owns 5,396,417 shares of the company’s stock worth $7,285,000 after acquiring an additional 1,234,268 shares during the last quarter. UBS Group AG grew its holdings in Ocugen by 373.2% during the 4th quarter. UBS Group AG now owns 4,849,353 shares of the company’s stock worth $6,547,000 after acquiring an additional 3,824,474 shares during the last quarter. State Street Corp increased its position in Ocugen by 193.6% in the 4th quarter. State Street Corp now owns 3,978,738 shares of the company’s stock valued at $5,371,000 after acquiring an additional 2,623,361 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Ocugen by 3.9% in the fourth quarter. Geode Capital Management LLC now owns 3,819,242 shares of the company’s stock worth $5,159,000 after acquiring an additional 142,050 shares during the last quarter. 10.27% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Ocugen

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: The FDA cleared Ocugen to begin the Phase 3 OCU410 trial for geographic atrophy associated with dry age-related macular degeneration. The program also received Regenerative Medicine Advanced Therapy designation, potentially enabling priority review and accelerated approval. Ocugen targets three BLAs by 2028
• Positive Sentiment: Ocugen completed a $130 million convertible-notes financing, using roughly $32.7 million to retire higher-cost Avenue Capital debt and extending its expected cash runway into 2028. Cash and restricted cash totaled $100.4 million at June 30. Ocugen second-quarter business update
• Positive Sentiment: The company reported progress across its late-stage pipeline: OCU410 Phase 3 is expected to start this quarter, OCU400 enrollment is complete with topline data expected in the first quarter of 2027, and OCU410ST data are anticipated in the second quarter of 2027. Ocugen Q2 2026 earnings call highlights
• Positive Sentiment: A proposed OCU400 licensing arrangement for the Middle East and North Africa could provide up to $255 million in sales milestones, royalties of 22% on net sales, and an upfront payment. Ocugen reports Q2 results and advances OCU410
• Neutral Sentiment: Second-quarter revenue was $1.49 million, above the $0.89 million analyst estimate, but remains small relative to the company’s development costs. Ocugen reports Q2 loss and beats revenue estimates
• Negative Sentiment: Ocugen’s quarterly loss widened to $0.07 per share from $0.05 a year earlier, missing the $0.05 consensus estimate. Research and development spending rose to $10.7 million, pushing total operating expenses to $17.9 million. Ocugen Q2 earnings miss as R&D costs rise
• Negative Sentiment: The financing improves liquidity but adds convertible debt and potential future share dilution. Ocugen also reported a $24.9 million net loss for the quarter and an accumulated deficit of $452.1 million, underscoring its ongoing dependence on capital markets.

Ocugen Stock Performance

Ocugen stock opened at $1.27 on Monday. The company has a market cap of $430.67 million, a PE ratio of -4.88 and a beta of 2.21. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 4.17. Ocugen, Inc. has a 1 year low of $0.96 and a 1 year high of $2.73. The company’s 50-day moving average is $1.34 and its two-hundred day moving average is $1.56.

Ocugen (NASDAQ:OCGN) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The firm had revenue of $1.49 million for the quarter, compared to the consensus estimate of $0.89 million. Equities analysts anticipate that Ocugen, Inc. will post -0.22 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on OCGN. Canaccord Genuity Group reduced their target price on shares of Ocugen from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Wednesday, May 27th. Wall Street Zen lowered shares of Ocugen from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Weiss Ratings cut shares of Ocugen from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 23rd. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $9.50.

Insider Transactions at Ocugen

In other Ocugen news, CFO Treerita Essali Johnson-Greene acquired 21,000 shares of Ocugen stock in a transaction on Monday, June 15th. The shares were purchased at an average cost of $1.23 per share, with a total value of $25,830.00. Following the completion of the purchase, the chief financial officer owned 521,000 shares in the company, valued at $640,830. The trade was a 4.20% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 3.95% of the company’s stock.

Ocugen Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.